Seminars in nuclear medicine最新文献_第7页

Current and Future Perspective of PET/CT in Response Assessment of Malignant Pleural Mesothelioma PET/CT在恶性胸膜间皮瘤反应评价中的现状及未来展望。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.001

Manar Badarna MD , Zohar Keidar MD, PhD , Elite Arnon-Sheleg MD

引用次数: 0

What Role Does PET/MRI Play in Musculoskeletal Disorders? PET/MRI在肌肉骨骼疾病中的作用?

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2023.11.004

Tugce Telli MD , Mélanie Desaulniers MD, FRCPC , Thomas Pyka MD , Federico Caobelli MD, FEBNM , Sophia Forstmann MD , Lale Umutlu MD , Wolfgang P. Fendler MD , Axel Rominger MD , Ken Herrmann MD, MBA , Robert Seifert MD, MBA

{"title":"What Role Does PET/MRI Play in Musculoskeletal Disorders?","authors":"Tugce Telli MD , Mélanie Desaulniers MD, FRCPC , Thomas Pyka MD , Federico Caobelli MD, FEBNM , Sophia Forstmann MD , Lale Umutlu MD , Wolfgang P. Fendler MD , Axel Rominger MD , Ken Herrmann MD, MBA , Robert Seifert MD, MBA","doi":"10.1053/j.semnuclmed.2023.11.004","DOIUrl":"10.1053/j.semnuclmed.2023.11.004","url":null,"abstract":"<div><div><span>Musculoskeletal disorders<span> of nononcological origin are one of the most frequent reasons for consultation. Patients suffering from musculoskeletal disorders also consult more than once for the same reason. This results in multiple clinical follow-ups after several radiological and serum examinations, the main ones including X-rays targeting the painful anatomical region and inflammatory serum parameters. As part of their work up, patients suffering from musculoskeletal disorders often require multisequence, multi-parameter MRI. PET/MRI is a promising imaging modality for their diagnosis, with the added advantage of being able to be performed in a single visit. PET/MRI is particularly useful for diagnosing osteomyelitis, </span></span>spondylodiscitis<span>, arthritis, many pediatric pathologies<span>, and a wide range of other musculoskeletal pathologies. PET/MRI is already used to diagnose malignant bone tumors such as osteosarcoma. However, current knowledge of the indications for PET/MRI in nononcological musculoskeletal disorders is based on studies involving only a few patients. This review focuses on the usefulness of PET/MRI for diagnosing nononcological musculoskeletal disorders.</span></span></div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 277-289"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138478517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

PET/MRI in Non-Small Cell Lung Cancer (NSCLC) 非小细胞肺癌（NSCLC）的PET/MRI。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.009

Fawziah Alorfi MD , Jamshed Bomanji MD, PhD , Linda Bertoletti MD , Francesco Fraioli MD

{"title":"PET/MRI in Non-Small Cell Lung Cancer (NSCLC)","authors":"Fawziah Alorfi MD , Jamshed Bomanji MD, PhD , Linda Bertoletti MD , Francesco Fraioli MD","doi":"10.1053/j.semnuclmed.2025.02.009","DOIUrl":"10.1053/j.semnuclmed.2025.02.009","url":null,"abstract":"<div><div>Lung cancer remains the leading cause of cancer-related deaths worldwide, with nonsmall cell lung cancer (NSCLC) accounting for 80%-85% of cases. Accurate imaging is critical for staging, treatment planning, and follow-up. While CT and PET/CT are standard imaging modalities, PET/MR is a relatively new and promising radiation free technique combining the potentiality of MRI with the metabolic information of PET scans, allowing undeniable advantages including: superior contrast resolution, particularly in soft tissues; functional information through specific MRI sequences (eg, diffusion-weighted and perfusion sequences), reflecting changes at a cellular level; and more superior sensitivity compared to CT and PET/CT for detecting metastases in common metastatic sites such as the brain, liver, adrenal glands, and bone. These advantages position PET/MR as a valuable tool in comprehensive lung cancer staging. While it is not yet a routine clinical tool, ongoing advancements in imaging technology, protocol optimization, and large-scale studies may establish PET/MR as a key component in the personalized management of lung cancer.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 234-239"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals 肺癌的发展模式：诊断、管理和放射性药物的最新趋势。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-03-01 DOI: 10.1053/j.semnuclmed.2025.02.005

Busra Cangut MD, MS, Rahman Akinlusi MD, Ava Mohseny MD, Nasrin Ghesani MD, Munir Ghesani MD

{"title":"Evolving Paradigms in Lung Cancer: Latest Trends in Diagnosis, Management, and Radiopharmaceuticals","authors":"Busra Cangut MD, MS, Rahman Akinlusi MD, Ava Mohseny MD, Nasrin Ghesani MD, Munir Ghesani MD","doi":"10.1053/j.semnuclmed.2025.02.005","DOIUrl":"10.1053/j.semnuclmed.2025.02.005","url":null,"abstract":"<div><div>Lung cancer is one of the most common and deadliest forms of cancer worldwide. Over the past two decades, significant changes have occurred in the classification of lung cancer, involving multidisciplinary input and emphasizing the growing contribution of immunohistochemistry and molecular techniques to morphology in the classification scheme. This comprehensive review will cover the background and epidemiology of lung cancer as well as advancements in its staging and management, including discussions of new surgical techniques, targeted therapies, and immunotherapy. The review will detail the role of 18F-FDG-PET-CT in lung cancer, highlighting its importance in staging, treatment response assessment, and recurrence detection. While immunotherapy has transformed lung cancer management and improved patient outcomes, it presents major challenges and opportunities for optimal assessment of treatment response in lung cancer patients using 18F-FDG-PET-CT. This review will also explore future directions, including a discussion of promising new targeted diagnostic radiopharmaceuticals for PET/CT imaging. Additionally, there will be a brief discussion of evolving and exciting treatment options for lung cancer using targeted therapeutic radiopharmaceuticals. Several case-based illustrations are included to exemplify the role of 18F-FDG-PET-CT in various clinical scenarios.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 2","pages":"Pages 264-276"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Role of AI in the Evaluation of Neuroendocrine Tumors: Current State of the Art 人工智能在神经内分泌肿瘤评估中的作用：最新进展。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-28 DOI: 10.1053/j.semnuclmed.2025.02.003

Felipe Lopez-Ramirez MD, Mohammad Yasrab MD, Florent Tixier PhD, Satomi Kawamoto MD, Elliot K. Fishman MD, Linda C. Chu MD

引用次数: 0

AI in Breast Cancer Imaging: An Update and Future Trends 人工智能在乳腺癌成像中的应用：最新进展和未来趋势。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-25 DOI: 10.1053/j.semnuclmed.2025.01.008

Yizhou Chen MA, M. Eng. , Xiaoliang Shao MD , Kuangyu Shi PhD , Axel Rominger MD, PhD , Federico Caobelli PD, MD, FEBNM

{"title":"AI in Breast Cancer Imaging: An Update and Future Trends","authors":"Yizhou Chen MA, M. Eng. , Xiaoliang Shao MD , Kuangyu Shi PhD , Axel Rominger MD, PhD , Federico Caobelli PD, MD, FEBNM","doi":"10.1053/j.semnuclmed.2025.01.008","DOIUrl":"10.1053/j.semnuclmed.2025.01.008","url":null,"abstract":"<div><div>Breast cancer is one of the most common types of cancer affecting women worldwide. Artificial intelligence (AI) is transforming breast cancer imaging by enhancing diagnostic capabilities across multiple imaging modalities including mammography, digital breast tomosynthesis, ultrasound, magnetic resonance imaging, and nuclear medicines techniques. AI is being applied to diverse tasks such as breast lesion detection and classification, risk stratification, molecular subtyping, gene mutation status prediction, and treatment response assessment, with emerging research demonstrating performance levels comparable to or potentially exceeding those of radiologists. The large foundation models are showing remarkable potential in different breast cancer imaging tasks. Self-supervised learning gives an insight into data inherent correlation, and federated learning is an alternative way to maintain data privacy. While promising results have been obtained so far, data standardization from source, large-scale annotated multimodal datasets, and extensive prospective clinical trials are still needed to fully explore and validate deep learning's clinical utility and address the legal and ethical considerations, which will ultimately determine its widespread adoption in breast cancer care. We hereby provide a review of the most up-to-date knowledge on AI in breast cancer imaging.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 358-370"},"PeriodicalIF":4.6,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143516707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Potential of Technetium and Rhenium Theranostics 锝和铼的治疗潜力。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-24 DOI: 10.1053/j.semnuclmed.2025.01.005

Geoffrey M. Currie , Eric M. Rohren

{"title":"Potential of Technetium and Rhenium Theranostics","authors":"Geoffrey M. Currie , Eric M. Rohren","doi":"10.1053/j.semnuclmed.2025.01.005","DOIUrl":"10.1053/j.semnuclmed.2025.01.005","url":null,"abstract":"<div><div>While theranostics has transformed the precision medicine landscape over the last decade, there is scope for the development of true theranostic pairs, e.g. diagnostic and therapeutic partners in which any physical, chemical, and biological differences are negligible to <em>in vivo</em> application. Although simple to state in theory, there are, in fact, limited options exhibiting optimal physical characteristics and wholly shared elements.</div><div>Further compounding real-world application of the traditional theranostic method are additional barriers. The use of PET/CT as the cornerstone of the diagnostic pair in theranostics creates inequity of access and opportunity based on socioeconomic and geographic factors, and the growing demand for both <sup>68</sup>Ga and <sup>177</sup>Lu is straining production capabilities globally. Improving access to theranostics globally will require novel thinking and infrastructure investment to ensure that patients of all economic and social backgrounds have access to this transformative technology.</div><div>An approach which is underdeveloped, but which may address gaps in health inequities and improve outcomes, is the application of the widely available generator-produced <sup>99m</sup>Tc for imaging and <sup>188</sup>Re for therapy. Despite favourable and near identical radiochemistry, the search for the next generation of theranostic radionuclide pairs seldom references technetium or rhenium radionuclides. Advances in SPECT/CT instrumentation and radiochemistry provide an opportunity to deliver theranostics to communities not serviced by PET-based theranostics. The <sup>188</sup>Re and <sup>99m</sup>Tc supply by daily elution of a generator affords significant convenience, flexibility and delayed biomolecule imaging. Low abundance gamma emissions of <sup>188</sup>Re allow serial imaging and dosimetry calculations. <sup>99m</sup>Tc / <sup>188</sup>Re theranostics could address inequity in access and opportunity to cutting edge theranostics.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 829-840"},"PeriodicalIF":5.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143503570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sharpening the Blade of Precision Theranostics 磨砺精准治疗之刃。

IF 5.9 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-24 DOI: 10.1053/j.semnuclmed.2025.01.007

Geoffrey M. Currie , Eric M. Rohren

{"title":"Sharpening the Blade of Precision Theranostics","authors":"Geoffrey M. Currie , Eric M. Rohren","doi":"10.1053/j.semnuclmed.2025.01.007","DOIUrl":"10.1053/j.semnuclmed.2025.01.007","url":null,"abstract":"<div><div>While theranostics is a new term for long-standing principles in nuclear medicine, recent advances have facilitated more personalized healthcare and precision medicine. Despite the widespread enthusiasm for theranostics and well established and standardized procedures, there are a number of opportunities to enhance practice and sharpen the blade of precision theranostics. A clear understanding of the requisites of an authentic theranostic pair reveals limitations in current approaches. Indeed, standardized dosing regimes based on activity dose as opposed to absorbed dose highlight the potential enhancements to outcomes and precision medicine that predictive dosimetry could bring. Such advances increase the demand for closer matching of biological and chemical properties of theranostic pairs. In turn, the need for more authentic or true theranostic pairs is revealed. While theranostics has provided a revolutionary toolkit for cancer management, advances in instrumentation, radiochemistry or clinical domains requires similar advances in the remaining domains. This discussion explores key considerations for an evolving theranostics landscape, recognising current best practice may fall short of precision medicine over coming years.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 5","pages":"Pages 841-855"},"PeriodicalIF":5.9,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143503572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial Intelligence for Drug Discovery: An Update and Future Prospects 人工智能用于药物发现：最新进展和未来展望。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-17 DOI: 10.1053/j.semnuclmed.2025.01.004

Harrison J. Howell BS , Jeremy P. McGale MA , Aurélie Choucair MD , Dorsa Shirini MD, MBA , Nicolas Aide MD, PhD , Michael A. Postow MD , Lucy Wang BA , Mickael Tordjman MD , Egesta Lopci MD, PhD , Augustin Lecler MD, PhD , Stéphane Champiat MD, PhD , Delphine L. Chen MD , Désirée Deandreis MD , Laurent Dercle MD, PhD

{"title":"Artificial Intelligence for Drug Discovery: An Update and Future Prospects","authors":"Harrison J. Howell BS , Jeremy P. McGale MA , Aurélie Choucair MD , Dorsa Shirini MD, MBA , Nicolas Aide MD, PhD , Michael A. Postow MD , Lucy Wang BA , Mickael Tordjman MD , Egesta Lopci MD, PhD , Augustin Lecler MD, PhD , Stéphane Champiat MD, PhD , Delphine L. Chen MD , Désirée Deandreis MD , Laurent Dercle MD, PhD","doi":"10.1053/j.semnuclmed.2025.01.004","DOIUrl":"10.1053/j.semnuclmed.2025.01.004","url":null,"abstract":"<div><div>Artificial intelligence (AI) has become a pivotal tool for medical image analysis, significantly enhancing drug discovery through improved diagnostics, staging, prognostication, and response assessment. At a high level, AI-driven image analysis enables the quantification and synthesis of previously qualitative imaging characteristics, facilitating the identification of novel disease-specific biomarkers, patient risk stratification, prognostication, and adverse event prediction. In addition, AI can assist in response assessment by capturing changes in imaging “phenotype” over time, allowing for optimized treatment plans based on real-time analysis. Integrating this emerging technology into drug discovery pipelines has the potential to accelerate the identification and development of new pharmaceuticals by assisting in target identification and patient selection, as well as reducing the incidence, and therefore cost, of failed trials through high-throughput, reproducible, and data-driven insights. Continued progress in AI applications will shape the future of medical imaging, ultimately fostering more efficient, accurate, and tailored drug discovery processes. Herein, we offer a comprehensive overview of how AI enhances medical imaging to inform drug development and therapeutic strategies.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 406-422"},"PeriodicalIF":4.6,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143449799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Evolution of Artificial Intelligence in Nuclear Medicine 人工智能在核医学中的发展。

IF 4.6 2区医学

Seminars in nuclear medicine Pub Date : 2025-02-10 DOI: 10.1053/j.semnuclmed.2025.01.006

Leonor Lopes MD , Alejandro Lopez-Montes PhD , Yizhou Chen MSc , Pia Koller MSc , Narendra Rathod PhD , August Blomgren MSc , Federico Caobelli MD , Axel Rominger PhD , Kuangyu Shi PhD , Robert Seifert MD

{"title":"The Evolution of Artificial Intelligence in Nuclear Medicine","authors":"Leonor Lopes MD , Alejandro Lopez-Montes PhD , Yizhou Chen MSc , Pia Koller MSc , Narendra Rathod PhD , August Blomgren MSc , Federico Caobelli MD , Axel Rominger PhD , Kuangyu Shi PhD , Robert Seifert MD","doi":"10.1053/j.semnuclmed.2025.01.006","DOIUrl":"10.1053/j.semnuclmed.2025.01.006","url":null,"abstract":"<div><div>Nuclear medicine has continuously evolved since its beginnings, constantly improving the diagnosis and treatment of various diseases. The integration of artificial intelligence (AI) is one of the latest revolutionizing chapters, promising significant advancements in diagnosis, prognosis, segmentation, image quality enhancement, and theranostics. Early AI applications in nuclear medicine focused on improving diagnostic accuracy, leveraging machine learning algorithms for disease classification and outcome prediction. Advances in deep learning, including convolutional and more recently transformer-based neural networks, have further enabled more precise diagnosis and image segmentation as well as low-dose imaging, and patient-specific dosimetry for personalized treatment. Generative AI, driven by large language models and diffusion techniques, is now allowing the process, interpretation, and generation of complex medical language and images. Despite these achievements, challenges such as data scarcity, heterogeneity, and ethical concerns remain barriers to clinical translation. Addressing these issues through interdisciplinary collaboration will pave the way for a broader adoption of AI in nuclear medicine, potentially enhancing patient care and optimizing diagnosis and therapeutic outcomes.</div></div>","PeriodicalId":21643,"journal":{"name":"Seminars in nuclear medicine","volume":"55 3","pages":"Pages 313-327"},"PeriodicalIF":4.6,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143400013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0